Business Wire

ONWARD

27.1.2021 17:02:08 CET | Business Wire | Press release

Share
ONWARD Announces Publication in Nature Demonstrating Blood Pressure Stabilization in People with Spinal Cord Injury

ONWARD today announced the publication of a study in the journal, Nature , which found targeted electrical spinal cord stimulation stabilizes blood pressure in people with spinal cord injury (SCI).

“A serious and underrecognized result of spinal cord injury is unstable blood pressure, which can have devastating consequences that reduce quality of life and are life threatening. Unfortunately, there are no effective therapies for unstable blood pressure after spinal cord injury,” said Dr. Aaron Phillips, PhD, a member of the Hotchkiss Brain Institute and Libin Cardiovascular Institute at the Cumming School of Medicine (CSM) and co-lead author of the study. “We created the first platform to understand the mechanisms underlying blood pressure instability after spinal cord injury, which allowed us to develop a new cutting-edge solution.”

Loss of movement and sensation are the most commonly known impacts of spinal cord injury, but SCI is also frequently accompanied by other effects that challenge activities of daily living. Blood pressure instability is one such effect, making it difficult for people with SCI to change body position – moving from lying to sitting to standing. In this study, researchers from University of Calgary, Swiss Federal Institute of Technology (EPFL), and University Hospital Lausanne (CHUV) demonstrated they could quickly and accurately normalize blood pressure with electrical spinal cord stimulation. Stabilization was observed in rodents and non-human primates for extended periods after acute and chronic spinal cord injury, and the approach also showed promise in humans.

This research is a breakthrough in the fundamental understanding of how blood pressure regulatory circuits function in people with SCI and sets the foundation for further studies assessing the use of electrical spinal cord stimulation to regulate blood pressure and other autonomic functions in people with SCI.

“We used similar concepts and technologies to restore walking after paralysis and are now pleased to leverage those advances to address this very common but serious effect of SCI,” said Dr. Grégoire Courtine, PhD, Professor at EPFL, Director of .NeuroRestore, and co-lead author of the study. “We look forward to working with ONWARD to conduct clinical trials in humans so this approach can be translated into a viable therapeutic option for people with SCI.”

This research will be further advanced by a $36 million contract granted by the United States Defense Advanced Research Project Agency (DARPA) for a five-year project to develop neurotherapeutics that bridge the gap between the spinal cord and the brain after spinal cord injury. The DARPA contract enables an alliance of 12 institutions around the world that includes EPFL, University of Calgary and ONWARD to conduct groundbreaking research in the pursuit of new therapies for spinal cord injury. DARPA has helped develop major technological advancements including the internet, GPS and Speech Interpretation and Recognition Interface (SIRI.)

About ONWARD

ONWARD (@onwdempowered ), formerly known as GTX Medical, is a medical technology company focused on the development and commercialization of innovative therapies to facilitate functional recovery of people with spinal cord injury. Driven by a mission to restore movement, independence, and health in people with spinal cord injury, ONWARD’s work builds on more than a decade of basic science and preclinical research conducted at the world’s leading neuroscience laboratories. ONWARD’s ARC Therapy, which can be delivered by implantable (ARCIM ) or external (ARCEX ) systems, is designed to deliver targeted, programmed stimulation of the spinal cord to restore movement and other functions in people with spinal cord injury, ultimately improving their quality of life. Both of ONWARD’s technology platforms have been awarded Breakthrough Device Designation by the FDA.

ONWARD is headquartered at the High Tech Campus in Eindhoven, the Netherlands and the EPFL Innovation Park in Lausanne, Switzerland, with a growing U.S. presence in Boston, Massachusetts, USA. For additional information about the company, please visit ONWD.com and follow us on Twitter and LinkedIn .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Media Release: Jannik Sinner and Allianz Announce Multi-Year Global Partnership29.1.2026 11:04:00 CET | Press release

Jannik Sinner becomes Global Brand Ambassador of the world’s most valuable insurance brand.The partnership broadens Allianz’s established sports collaborations; the large tennis fan base worldwide will drive emotional engagement with Allianz.“We’re here to serve” captures the spirit of both partners; joint projects with The Jannik Sinner Foundation aim to support children’s future. Tennis star Jannik Sinner and Allianz Group announced a multi-year global partnership today, with the leading insurer and asset manager becoming an official partner of the four-time Grand Slam champion. Boasting approximately 300 million fans worldwide and a billion-strong ATP global fan base, tennis is the second-most popular sport behind football across Allianz key markets. A cornerstone of the collaboration is empowering children and youth through education and sport, providing them with enhanced opportunities for growth, health, and future success. This partnership also expands Allianz's involvement in s

How Aker Security Builds Control Rooms for Real-Time Decision-Making29.1.2026 10:00:00 CET | Press release

In a new case, Aker Security demonstrates how a control room built on Cyviz’ technology platform functions as the operational nerve center for decision-making, collaboration, and preparedness. In today’s security landscape, the challenge lies in aggregating, visualizing, and using large volumes of data effectively in situations where time, precision, and coordination are critical. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260129578139/en/ GSOC Aker Security oversees security and preparedness for large parts of the Group, covering several thousand employees. Its services include travel security, global event and incident monitoring, crisis management, and security advisory services. "We approached Cyviz because we needed a solution that could bring everything together on a single platform, while at the same time supporting the way we actually work operationally," says Tonje Evensen Bråthen, Head of the Global Security Op

Multi-Color Corporation Initiates Implementation of Restructuring Agreement29.1.2026 07:58:00 CET | Press release

Commences Prepackaged Chapter 11 Process As Part of Previously Announced Restructuring Support Agreement to Reset Balance Sheet and Position Company for Long-Term Growth and InvestmentRestructuring Supported by CD&R and More Than Supermajority of Senior Secured Lenders Who Have Agreed to Backstop Nearly $890 Million Investment; Provides More Than $500 Million of New Liquidity Upon EmergenceAll Global Operations and Service to Customers Expected to Continue Without Interruption; All Trade Vendors and Suppliers Expected to be Paid in FullProvides for $250 Million of New Money Debtor-in-Possession Financing to Capitalize the Business Throughout the Prepackaged Chapter 11 Process Multi-Color Corporation (“MCC” or the “Company”), a global leader in prime label solutions, today announced that to implement the previously announced restructuring support agreement (the “RSA”), the Company has commenced its prepackaged Chapter 11 filing in the United States Bankruptcy Court for the District of N

Takeda Reports Third-Quarter FY2025 Results: Updates Full Year Outlook to Reflect VYVANSE® Generics Impact, OPEX Discipline and FX Tailwind; Progressing Toward Three Transformative Launches Ahead29.1.2026 07:37:00 CET | Press release

Year-to-Date Revenue Declined by 2.8% at Constant Exchange Rate (CER), 3.3% atActual Exchange Rates (AER);Impact of VYVANSE® Generics is Tapering OffCore Operating Profit Declined by 3.4% at both CER and AER Year to DateReported Operating Profit Increased by 1.2% at AER Year to Date, Lower Restructuring Expenses More Than Offset Impairment Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the third quarter of fiscal year 2025 (nine months ended December 31, 2025). The gap between incremental Growth & Launch Products revenue and VYVANSE erosion is narrowing, and operational efficiencies drove year-on-year reductions in operating expenses, including R&D. The company raised its full-year forecasts based on cost discipline and FX tailwind, while its Revenue Management Guidance has been updated primarily due to the impact of VYVANSE generics. Takeda is positioned for long-term growth and has multiple late-stage programs with multibillion-dollar peak revenue potential. Follow

Galderma Unveils ‘Wake Up To Restylane’, Underscoring Restylane as the Ideal Hyaluronic Acid Treatment for Always-On Natural Beauty29.1.2026 07:00:00 CET | Press release

‘Wake Up To Restylane®’ is a global campaign designed to meet the rising demand for natural-looking always-on results, helping people wake up looking refreshed and rested, and reframes Restylane treatments from a clinical procedure into an always-on beauty regimen Backed by 30 years of science, the Restylane portfolio is the only hyaluronic acid (HA) range offering four distinct technologies, designed to deliver personalized natural-looking outcomes that provide contour, definition, and hydration, with HA closest to the skin’s own1-7 This launch builds on new clinical data presented at the International Master Course on Aging Science (IMCAS) World Congress 2026, confirming Restylane’s proven efficacy and versatility across multiple facial areas and the décolletage8-11 Galderma (SIX: GALD), the pure-play dermatology category leader, has launched ‘Wake Up To Restylane’, a global campaign that showcases Restylane as an everyday beauty ally. Aligned with the growing desire for effortless,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye